 | | Targets for anticoagulants |
|  | | Overview: phase III clinical trials of new oral anticoagulants |
|
 | | Overview: phase III clinical trials of new oral anticoagulants |
|  | | VKAs are more effective than antiplatelet therapy for stroke prevention |
|
 | | RE-LY: A Non-inferiority Trial |
|  | | Stroke or Systemic Embolism |
|
 | | Ischaemic/Unspecified Stroke |
|  | | Haemorrhagic Stroke |
|
 | | Bleeding and Myocardial Infarction |
|  | | Dabigatran 150 mg vs. 110 mg |
|
 | | Common Adverse Events |
|  | | Study Design |
|
 | | Primary Efficacy Outcome Stroke and non-CNS Embolism |
|  | | Primary Efficacy Outcome Stroke and non-CNS Embolism |
|
 | | Key Secondary Efficacy Outcomes |
|  | | Key Secondary Efficacy Outcomes |
|
 | | Time in Therapeutic Range (TTR) INR Data |
|  | | Primary Efficacy Outcome by Quartiles of cTTR Stroke and non-CNS Embolism |
|
 | | Primary Safety Outcomes |
|  | | Primary Safety Outcomes |
|
 | | Adverse Events and Liver Enzyme Data |
|  | | Summary |
|
 | | Baseline patient demographics: comparison of ROCKET AF with previous VKA-controlled trials |
|
Deel deze pagina met collega's en vrienden: